A phase II trial of SGI-110 in patients with ipss high and int 2 myelodysplastic syndrome, acute myeloid leukemia with 20-30% marrow blasts and chronic myelomonocytic leukemia type 2 not responding to azacitidine or decitabine after at least 6 courses or relapsing after a response

Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2014
This article has no abstract
Epistemonikos ID: 5e31f99e7584f98168801e9e10f3eafa92cd9b2a
First added on: Jan 22, 2025